Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System

Core Insights - Inspira Technologies is accelerating the commercialization of its INSPIRA ART100 system following successful clinical implementations in the U.S. [1][2] - The company is engaged in discussions with governmental health departments and private organizations to structure rollouts that align with clinical priorities [3] - Deliveries of the ART100 are expected to begin in the second half of 2025, contingent on logistical and regulatory alignment [3] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with the ART100 system cleared by the U.S. FDA for cardiopulmonary bypass and ECMO procedures [5] - The company is also developing the next-generation INSPIRA ART500 and the HYLA blood sensor, aiming to support its innovation pipeline while focusing on near-term revenue from the ART100 [4] - Inspira is positioned as an attractive platform within the critical care and MedTech landscape, reflecting broader industry trends such as consolidation and cross-sector collaboration [5]